Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELITE: Modified Zipper Therapy in AQP4-IgG+ NMOSD
NCT07420296Phase 3Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of eculizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Tianjin Medical University General Hospital. Started Jan 2026; status: recruiting.
02
Drugs
eculizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT07420296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07420296.